Condition (MeSH)
Hemangioendothelioma, Epithelioid
ClinicalTrials.gov lists 13 trials for Hemangioendothelioma, Epithelioid or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
13 of the 13 trials are tagged with Hemangioendothelioma, Epithelioid itself; the rest are tagged with a narrower condition beneath it.
When did Hemangioendothelioma, Epithelioid trials start? (10)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2024 | 2 |
| 2023 | 1 |
| 2022 | 1 |
| 2021 | 1 |
| 2018 | 1 |
| 2017 | 2 |
| 2016 | 1 |
| 2012 | 1 |
| 2010 | 1 |
No forecast is made for this condition: it averages 1.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hemangioendothelioma, Epithelioid trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 3 |
| Phase 2 | 6 |
| Not applicable | 1 |
| Observational | 1 |
How many Hemangioendothelioma, Epithelioid trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 5 |
| Completed | 6 |
| Terminated | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hemangioendothelioma, Epithelioid trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 2 |
| BridGene Biosciences Inc. | 1 |
| CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 1 |
| Ikena Oncology | 1 |
Interventions as named in the registry (15)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Ifosfamid | 2 |
| Pazopanib Pill | 2 |
| Doxorubicine | 2 |
| Gemcitabine/Gemzar | 1 |
| Nab-Sirolimus | 1 |
Showing 5 of 15 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hemangioendothelioma, Epithelioid trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Anemia | 8 | 4 |
| Colitis | 8 | 3 |
| Dyspnea | 8 | 4 |
| Pleural effusion | 8 | 5 |
| Death NOS | 7 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Hemangioendothelioma, Epithelioid? (30)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years. | European journal of cancer (Oxford, England : 1990) | 2023 | Yes |
| The TAZ-CAMTA1 Fusion Protein Promotes Tumorigenesis via Connective Tissue Growth Factor and Ras-MAPK Signaling in Epithelioid Hemangioendothelioma. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2022 | Yes |
| Epithelioid hemangioendothelioma in children: The European Pediatric Soft Tissue Sarcoma Study Group experience. | Pediatric blood & cancer | 2022 | Yes |
| Activity of sirolimus in patients with progressive epithelioid hemangioendothelioma: A case-series analysis within the Italian Rare Cancer Network. | Cancer | 2021 | Yes |
| Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature. | Cancer medicine | 2021 | Yes |
Showing 5 of 30 publications.
Prevalence (3)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Epithelioid hemangioendothelioma | Point prevalence | <1 / 1 000 000 | Worldwide | Not stated | Unspecified |
| Epithelioid hemangioendothelioma | Point prevalence | <1 / 1 000 000 | Worldwide | Not stated | Exact |
| Epithelioid hemangioendothelioma | Point prevalence | <1 / 1 000 000 | Worldwide | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Epithelioid hemangioendothelioma | 157791 | Exact | Orphadata Science knowledge files, Product 1 |
| Epithelioid hemangioendothelioma | 157791 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.